79183-24-7

Usage

Uses

Used in Pharmaceutical Industry:
1-(2,4-DICHLOROBENZYL)-1H-INDOLE-2,3-DIONE is used as a chemical intermediate for the development of new drugs or medications. Its unique structure and properties make it a promising candidate for creating novel therapeutic agents.
Used in Chemical Research:
In the field of chemical research, 1-(2,4-DICHLOROBENZYL)-1H-INDOLE-2,3-DIONE serves as a valuable compound for studying its properties and potential reactions with other molecules. This can lead to the discovery of new chemical processes and the creation of additional useful compounds.
Used in Drug Development:
1-(2,4-DICHLOROBENZYL)-1H-INDOLE-2,3-DIONE is used as a building block in the synthesis of various pharmaceuticals. Its presence in the development pipeline indicates its potential role in the creation of innovative treatments for a range of diseases and conditions.
Overall, 1-(2,4-DICHLOROBENZYL)-1H-INDOLE-2,3-DIONE is a versatile compound with diverse potential applications across different industries, primarily in the pharmaceutical sector. Its unique structure and properties make it an interesting target for further research and development, which may lead to significant scientific and medical advancements in the future.

Upstream product

• 91-56-5 indole-2,3-dione 
• 20443-99-6 2,4-dichlorobenzyl bromide 

Downstream Products

• 1345838-02-9 (E)-ethyl 2-(1-(2,4-dichlorobenzyl)-2-oxoindolin-3-ylidene)acetate 
• 1332882-58-2 C₂₂H₁₅Cl₂N₃O₂ 
• 1267807-76-0 diethyl {[(3E)-1-(2,4-dichlorobenzyl)-2-oxoindolin-3-ylidene]methyl}phophonate 

Relevant academic research and scientific papers

Discovery of Isatin-Based Carbohydrazones as Potential Dual Inhibitors of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase

Using ligand-based design strategy, a set of isatin-3-carbohydrazones was designed, synthesized and evaluated for dual fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) inhibition properties. Compound 5-chloro-N′-(5-chloro-2-oxoindolin-3-ylidene)-2-hydroxybenzohydrazide (13 b) emerged as a potent MAGL inhibitor with nanomolar activity (IC50=3.33 nM), while compound 5-chloro-N′-(1-(4-fluorobenzyl)-2-oxoindolin-3-ylidene)-2-hydroxybenzohydrazide (13 j) was the most potent selective FAAH inhibitor (IC50=37 nM). Compound 5-chloro-N′-(6-chloro-2-oxoindolin-3-ylidene)-2-hydroxybenzohydrazide (13 c) showed dual FAAH-MAGL inhibitory activity with an IC50 of 31 and 29 nM respectively. Enzyme kinetics studies revealed that the isatin-based carbohydrazones are reversible inhibitors for both FAAH and MAGL. Further, blood-brain permeability assay confirmed that the lead compounds (13 b, 13 c, 13 g, 13 m and 13 q) are suitable as CNS candidates. Molecular dynamics simulation studies revealed the putative binding modes and key interactions of lead inhibitors within the enzyme active sites. The lead dual FAAH-MAGL inhibitor 13 c showed significant antioxidant activity and neuroprotection in the cell-based cytotoxicity assay. In summary, the study yielded three potent FAAH/MAGL inhibitor compounds (13 b, 13 c and 13 j) with acceptable pharmacokinetic profile and thus can be considered as promising candidates for treating neurological and mood disorders.

Synthesis, in vitro α-glucosidase inhibitory activity and docking studies of novel chromone-isatin derivatives

A novel series of chromone-isatin derivatives 6a–6p were designed, synthesized and characterized by 1H NMR, 13C NMR and HRMS. These novel synthetic compounds were evaluated for inhibitory activity against yeast α-glucosidase enzyme. The results of biological test have shown that all tested compounds exhibited excellent to potent inhibitory activity in the range of IC50 = 3.18 ± 0.12–16.59 ± 0.17 μM as compared to the standard drug acarbose (IC50 = 817.38 ± 6.27 μM). Compound 6j (IC50 = 3.18 ± 0.12 μM) with a hydroxyl group at the 7-position of chromone and a 4-bromobenzyl group at the N1-positions of isatin, was found to be the most active compound among the series. Furthermore, molecular docking study was performed to help understand binding interactions of the most active analogs with α-glucosidase enzyme. These results indicated that this class of compounds had potential for the development of anti-diabetic agents.